These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 35882450)
1. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. Sigaud R; Rösch L; Gatzweiler C; Benzel J; von Soosten L; Peterziel H; Selt F; Najafi S; Ayhan S; Gerloff XF; Hofmann N; Büdenbender I; Schmitt L; Foerster KI; Burhenne J; Haefeli WE; Korshunov A; Sahm F; van Tilburg CM; Jones DTW; Pfister SM; Knoerzer D; Kreider BL; Sauter M; Pajtler KW; Zuckermann M; Oehme I; Witt O; Milde T Neuro Oncol; 2023 Mar; 25(3):566-579. PubMed ID: 35882450 [TBL] [Abstract][Full Text] [Related]
2. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331 [TBL] [Abstract][Full Text] [Related]
3. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372 [TBL] [Abstract][Full Text] [Related]
4. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440 [TBL] [Abstract][Full Text] [Related]
5. Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). Germann UA; Furey BF; Markland W; Hoover RR; Aronov AM; Roix JJ; Hale M; Boucher DM; Sorrell DA; Martinez-Botella G; Fitzgibbon M; Shapiro P; Wick MJ; Samadani R; Meshaw K; Groover A; DeCrescenzo G; Namchuk M; Emery CM; Saha S; Welsch DJ Mol Cancer Ther; 2017 Nov; 16(11):2351-2363. PubMed ID: 28939558 [TBL] [Abstract][Full Text] [Related]
6. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Selt F; Hohloch J; Hielscher T; Sahm F; Capper D; Korshunov A; Usta D; Brabetz S; Ridinger J; Ecker J; Oehme I; Gronych J; Marquardt V; Pauck D; Bächli H; Stiles CD; von Deimling A; Remke M; Schuhmann MU; Pfister SM; Brummer T; Jones DT; Witt O; Milde T Oncotarget; 2017 Feb; 8(7):11460-11479. PubMed ID: 28002790 [TBL] [Abstract][Full Text] [Related]
7. Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models. Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217 [TBL] [Abstract][Full Text] [Related]
8. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma. Leclair NK; Lambert W; Roche K; Gillan E; Gell JJ; Lau CC; Wrubel G; Knopf J; Amin S; Anderson M; Martin JE; Bookland MJ; Hersh DS Neurosurg Focus; 2022 Dec; 53(6):E15. PubMed ID: 36455272 [TBL] [Abstract][Full Text] [Related]
9. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119 [TBL] [Abstract][Full Text] [Related]
10. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Jiang H; Xu M; Li L; Grierson P; Dodhiawala P; Highkin M; Zhang D; Li Q; Wang-Gillam A; Lim KH Mol Cancer Ther; 2018 Oct; 17(10):2144-2155. PubMed ID: 30065098 [TBL] [Abstract][Full Text] [Related]
11. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Sullivan RJ; Infante JR; Janku F; Wong DJL; Sosman JA; Keedy V; Patel MR; Shapiro GI; Mier JW; Tolcher AW; Wang-Gillam A; Sznol M; Flaherty K; Buchbinder E; Carvajal RD; Varghese AM; Lacouture ME; Ribas A; Patel SP; DeCrescenzo GA; Emery CM; Groover AL; Saha S; Varterasian M; Welsch DJ; Hyman DM; Li BT Cancer Discov; 2018 Feb; 8(2):184-195. PubMed ID: 29247021 [TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity. Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591 [TBL] [Abstract][Full Text] [Related]
13. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853 [TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. Vo KT; Sabnis AJ; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Jaju A; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW JCO Precis Oncol; 2024 Jun; 8():e2400103. PubMed ID: 38935895 [TBL] [Abstract][Full Text] [Related]
15. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
16. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles. Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393 [TBL] [Abstract][Full Text] [Related]
17. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Ryall S; Zapotocky M; Fukuoka K; Nobre L; Guerreiro Stucklin A; Bennett J; Siddaway R; Li C; Pajovic S; Arnoldo A; Kowalski PE; Johnson M; Sheth J; Lassaletta A; Tatevossian RG; Orisme W; Qaddoumi I; Surrey LF; Li MM; Waanders AJ; Gilheeney S; Rosenblum M; Bale T; Tsang DS; Laperriere N; Kulkarni A; Ibrahim GM; Drake J; Dirks P; Taylor MD; Rutka JT; Laughlin S; Shroff M; Shago M; Hazrati LN; D'Arcy C; Ramaswamy V; Bartels U; Huang A; Bouffet E; Karajannis MA; Santi M; Ellison DW; Tabori U; Hawkins C Cancer Cell; 2020 Apr; 37(4):569-583.e5. PubMed ID: 32289278 [TBL] [Abstract][Full Text] [Related]
18. Combined BRAF Zhang J; Yao TW; Hashizume R; Hariono S; Barkovich KJ; Fan QW; Prados M; James CD; Weiss WA; Nicolaides T J Neurooncol; 2017 Feb; 131(3):495-505. PubMed ID: 27848137 [TBL] [Abstract][Full Text] [Related]
19. ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo. Yu Y; Zhao Y; Choi J; Shi Z; Guo L; Elizarraras J; Gu A; Cheng F; Pei Y; Lu D; Fabbri M; Agarwal S; Zhang C; Jung SY; Foster JH; Yang J Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428626 [TBL] [Abstract][Full Text] [Related]